Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/IIa, Single Center, Randomized, Open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects

Next Previous
Trial Profile

A Phase Ib/IIa, Single Center, Randomized, Open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encofosbuvir (Primary) ; Sofosbuvir
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms HEC110114
  • Sponsors Sunshine Lake Pharma

Most Recent Events

  • 09 Sep 2020 Status changed from not yet recruiting to completed.
  • 16 Mar 2020 Planned initiation date changed from 10 Feb 2020 to 20 Apr 2020.
  • 19 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top